Rituximab therapy for life-threatining immune hemolytic anemia in a liver tranplant recipient: A case report

Akyildiz M., Karasu Z. , Cagirgan S., Kilic M., Tokat Y.

TRANSPLANTATION PROCEEDINGS, vol.36, no.5, pp.1492-1493, 2004 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 36 Issue: 5
  • Publication Date: 2004
  • Doi Number: 10.1016/j.transproceed.2004.05.042
  • Page Numbers: pp.1492-1493


Rituximab an anti-CD20 chimeric monoclonal antibody directed against the CD20 antigen on B lymphocytes, has been demonstrated to be highly effective for B-cell depletion. Because of its biological properties, it has become as a treatment option for a variety of autoimmune diseases. We report successful treatment of a 25-year-old male cadaveric liver retransplant recipient who displayed severe immune hemolytic anemia with rituximab, despite no previous response to corticosteroids plus intravenous immune globulin therapy.